Nephron Pharmaceuticals supports S.C. Governor’s School for the Arts and Humanities with funding for scholarshipsNephron Pharmaceuticals continued support of educational opportunities by announcing scholarships see more
The South Carolina Governor’s School for the Arts and Humanities received a $13,800 gift from Nephron Pharmaceuticals to support meal plan scholarships for Midlands students attending the school’s residential high school program.
“Nephron Pharmaceuticals Corporation is so proud to support arts education in our state. I have seen first-hand the impact of an arts education on the mind of a scientist, and it’s a beautiful thing. Look at a trained violinist and a pharmaceutical product developer. Both pursuits require repetition, dedication, critical thinking and the ability to solve a problem from a variety of angles,” said Lou Kennedy, CEO of Nephron Pharmaceuticals. “At Nephron, we’re always looking for critical thinkers and problem solvers, and that is why we are so passionate about supporting the arts as well as the sciences. We are proud to be a sponsor the South Carolina Governor’s School for the Arts and Humanities, and I encourage my fellow CEOs to support arts education across our state. We’re playing the long game here, and we aim to win.”
“While the Governor’s School for the Arts is a state-funded and tuition-free public high school, there are still meal plan fees that would present a financial barrier for many families if it weren’t for the support of our generous individual and corporate donors,” said Dr. Cedric Adderley, S.C. Governor’s School for the Arts and Humanities president. “Thanks to Nephron Pharmaceuticals, our emerging artists can pursue their dreams without worrying about costs.”
While tuition is free for all students attending for the full school year, about 30 percent of Governor’s School for the Arts students receive financial assistance from the Governor’s School for the Arts Foundation to pay for the $3,500 meal plan each year. This plan includes three meals per day for seven days per week during the nine-month school year. Nephron’s gift will provide meal plan scholarships to four Midlands students during the 2018-2019 school year.
Currently, 52 of the Governor’s School for the Arts’ 236 high school students are from the Midlands region, including Calhoun, Fairfield, Kershaw, Lexington, Orangeburg, Richland, Saluda, and Sumter counties. These students were selected based on their talents exhibited through a comprehensive application and audition process.
To learn more about the S.C. Governor’s School for the Arts & Humanities, follow @SCGSAH on social media and visit http://www.scgsah.org.
Nine Nephron employees to earn their Community Pharmacy Technician certificates at no cost... see more
Nephron Pharmaceuticals Corp. is partnering with Apprenticeship Carolina to provide nine Nephron employees a chance to earn a Community Pharmacy Technician certificate at Midlands Technical College. Apprenticeship Carolina is a division of the S.C. Technical College System. Read on for full details.
SCBIO has named its 2018 Board of Directors and Board Chair see more
SCBIO has announced its 2018 Board of Directors and Executive Committee following formal confirmation at the life science organization’s December 2017 meeting in Columbia. Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2018 Board Chair.
Ms. Kennedy joined Nephron Pharmaceuticals in 2001, and assumed the position of President and CEO in 2007. She has held a variety of marketing and operational roles during her career and has helped Nephron Pharmaceuticals grow by 300% and increased shipped product to one billion doses each of the last seven years. Nephron recently built a state of the art manufacturing facility in West Columbia, South Carolina and, with her husband Bill, helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy.
Joining Ms. Kennedy as officers on the SCBIO Executive Committee will be Craig Walker, CEO of VidiStar LLC as Vice Chair; Michael Rusnak, Executive Director of the Medical University of South Carolina Research Foundation as Treasurer; and Kathryn Cole Becker, Principal of Translational Science Solutions as Secretary. Additional members of the Executive Committee are Jeff Stover, Special Counsel with Haynsworth Sinkler Boyd, PA as Legal Officer; Stephanie Yarbrough, Partner with Womble Bond Dickinson, LLP as Annual Conference Officer; Bryan Davis, Operations Manager with Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; and Sam Konduros, President and CEO of SCBIO. Immediate Past Chair, Erin Ford, who now serves as the organization’s inaugural Vice President, was honored for her extraordinary board service during the December Board meeting.
Also elected to the 22-member Board of Directors for SCBIO are Darralyn Alexander, President of Reimbursement Strategies LLC; Mandy Brawley, Deputy Director of the South Carolina Department of Commerce; Jerry Chang, Vice President of Business Development for BioD; Matthew Couvillion, Attorney with the Wyche Law Form; J.J. Darby, State Government Affairs Leader for Johnson & Johnson Services; Tressa Gardner, Associate Vice president of the Southeastern Institute of Manufacturing and Technology at Florence-Darlington Technical College; and Mike Graney, Vice President for Global Business Development of the Charleston Regional Development Alliance.
Completing the 2018 Board of Directors for SCBIO are Chad Hardaway, Associate Director of the Office of Economic Engagement at the University of South Carolina; Willard Harms, VP of Medical Affairs for Blue Cross Blue Shield of South Carolina; Dr. Martine LaBerge, Chair of Clemson University’s Department of Bioengineering; Marc Metcalf, Business Recruitment Officer of the Upstate SC Alliance; Kathy Phlegar, President of Phlegar & Associates; Christine Dixon Thiesing, Director of Academic Programs for the South Carolina Research Authority; and Courtney Warren, Life Sciences Practice Chair for Marsh & McLennan Agency.
SCBIO President and CEO Konduros praised the Board and Executive Committee noting, “With the important work we are undertaking to actively advance life sciences R&D, biotech, med-tech, and digital health industries in South Carolina, we require strong, expert leadership from all across the state, fully integrating the business, education and economic development sectors. I am confident that these diverse leaders who reside in communities ranging from Murrells Inlet to Florence in addition to Greenville, Columbia, and Charleston, will effectively champion our vision of building the business of life sciences in South Carolina in 2018 and for years to come.”
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry already has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
The Board of Directors is the policy- and strategy-making body of the organization, and meets regularly to receive updates on SCBIO business and objectives, as well as domestic and global initiatives. The Executive Committee serves roles specific to SCBIO operations, focus areas and strategies.
SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
Nephron announces 5% salary increases thanks to tax cuts law see more
WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation (Nephron) CEO Lou Kennedy today announced five percent increases for all employees with the exception of commissioned employees. The raises are a direct result of the Tax Cuts and Jobs Act that was signed into law last week by President Donald Trump.
“We are excited that the Tax Cuts and Jobs Act has given us an opportunity to recognize their hard work and sacrifices with well-deserved raises”, said Lou Kennedy, CEO of Nephron.
Elected officials – including The Honorable Henry McMaster, Governor of South Carolina, U.S. Senator Lindsey Graham, Congressman Joe Wilson, state legislators and local elected officials – joined Kennedy and Nephron employees for today’s announcement celebration at the company’s West Columbia headquarters. Both of South Carolina’s U.S. Senators and six of the state’s seven members of the U.S. House of Representatives voted in favor of the Tax Cuts and Jobs Act.
"I am grateful that the tax cuts House Republicans worked so hard to pass have had an immediate impact in the district,” said Congressman Joe Wilson. “I congratulate Lou and Bill Kennedy, as well as Nephron's entire team, on today’s announcement, and I wish them continued success.”
Nephron is a manufacturer of respiratory and compounded 503B outsourcing medications that employs 640 people in West Columbia. The company, which launched 34 new products in 2017, recently announced a $12.5 million expansion and expects to add 125 additional employees by June 2018.
Fifty percent of Nephron employees attended South Carolina universities or technical colleges. Nephron founder Bill Kennedy and CEO Lou Kennedy are University of South Carolina graduates and South Carolinians. The company is part of the life sciences industry in the State. This industry has a total $11.4 billion annual impact on the State economy.
For more information about Nephron, visit http://www.nephronpharm.com.